Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Oversight By House To Focus On User Fees, Compounding Law

This article was originally published in The Pink Sheet Daily

Executive Summary

Among the Energy and Commerce Committee’s priorities are ensuring correct implementation of the generic drug and biosimilar user fee programs, whose launches have experienced some hiccups.

Advertisement

Related Content

Biosimilars: FDA, EMA Developing Common Data Package Guidance
PhRMA, BIO’s PDUFA V Application Tracker Could Inform “Course Corrections”
Teva’s G-CSF Product Clears FDA, Leaving Appeal Of Biosimilar Pathway Uncertain
FDASIA Study Mandates Focus On Performance, But Could Slow Reviews

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077149

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel